Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin versus dapagliflozin for liver and pancreatic fat in adults with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease
ChiCTR2400082485Phase 4Not yet recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of henagliflozin and dapagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Foshan First People's Hospital. Primary endpoint: Liver and pancreatic fat content. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
henagliflozindapagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400082485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082485.